Breakdown | |||||
TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
378.42M | 442.74M | 410.60M | 413.75M | 389.52M | 428.41M | Gross Profit |
376.89M | 337.95M | 409.18M | 412.23M | 386.39M | 404.54M | EBIT |
108.55M | -945.43M | 250.34M | 232.26M | 142.94M | 120.12M | EBITDA |
106.14M | -924.86M | 261.44M | 233.33M | 141.90M | 101.13M | Net Income Common Stockholders |
24.98M | -1.00B | 175.06M | 528.45M | 106.18M | -15.31M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
173.17M | 92.15M | 656.20M | 620.13M | 362.56M | 177.02M | Total Assets |
332.05M | 471.07M | 1.10B | 1.13B | 559.24M | 402.75M | Total Debt |
413.92M | 715.54M | 415.92M | 475.80M | 453.70M | 431.22M | Net Debt |
240.75M | 623.38M | -240.29M | -144.33M | 91.14M | 254.20M | Total Liabilities |
528.42M | 817.37M | 448.14M | 521.02M | 496.60M | 496.00M | Stockholders Equity |
-196.37M | -346.30M | 652.38M | 605.91M | 62.64M | -93.25M |
Cash Flow | Free Cash Flow | ||||
123.82M | 183.15M | 273.63M | 261.63M | 166.99M | 3.54M | Operating Cash Flow |
124.17M | 183.43M | 273.76M | 261.89M | 168.84M | 10.72M | Investing Cash Flow |
-4.33M | -1.03B | -136.00K | -265.00K | -1.84M | -11.14M | Financing Cash Flow |
-142.99M | 277.16M | -237.55M | -4.55M | 18.55M | -1.19M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
79 Outperform | $2.87B | 12.33 | 38.89% | ― | 31.85% | ― | |
75 Outperform | $171.31B | 42.18 | 67.55% | 2.86% | 18.64% | -39.39% | |
68 Neutral | $10.69B | 33.14 | 14.16% | ― | 24.81% | 33.67% | |
64 Neutral | $125.40B | ― | -3.15% | ― | 11.64% | -114.72% | |
60 Neutral | $13.17B | 249.74 | 0.76% | ― | 14.76% | -88.32% | |
49 Neutral | $236.84M | 142.59 | -8.02% | ― | -12.48% | 99.74% | |
49 Neutral | $6.84B | 0.05 | -53.14% | 2.48% | 24.49% | -3.26% |
On January 17, 2025, Ironwood Pharmaceuticals announced a significant workforce reduction of approximately 50% to streamline operations and focus on its strategic pipeline, affecting mainly field-based sales employees. This move is expected to result in charges of $20.0 to $25.0 million, with most costs incurred in the first half of 2025. Additionally, on January 29, 2025, Gregory Martini was promoted to Senior Vice President, Chief Financial Officer, effective January 27, 2025, succeeding Thomas McCourt in this role.